AR023727A1 - Compuestos empleados en el tratamiento de padecimientos inflamatorios - Google Patents

Compuestos empleados en el tratamiento de padecimientos inflamatorios

Info

Publication number
AR023727A1
AR023727A1 ARP990106429A ARP990106429A AR023727A1 AR 023727 A1 AR023727 A1 AR 023727A1 AR P990106429 A ARP990106429 A AR P990106429A AR P990106429 A ARP990106429 A AR P990106429A AR 023727 A1 AR023727 A1 AR 023727A1
Authority
AR
Argentina
Prior art keywords
treatment
inflammatory
matters
compounds used
therapy
Prior art date
Application number
ARP990106429A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR023727A1 publication Critical patent/AR023727A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP990106429A 1998-12-18 1999-12-15 Compuestos empleados en el tratamiento de padecimientos inflamatorios AR023727A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9828074.6A GB9828074D0 (en) 1998-12-18 1998-12-18 Therapeutically useful compounds

Publications (1)

Publication Number Publication Date
AR023727A1 true AR023727A1 (es) 2002-09-04

Family

ID=10844608

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106429A AR023727A1 (es) 1998-12-18 1999-12-15 Compuestos empleados en el tratamiento de padecimientos inflamatorios

Country Status (26)

Country Link
US (1) US6867192B1 (https=)
EP (1) EP1140837B1 (https=)
JP (1) JP4431282B2 (https=)
KR (1) KR20010101258A (https=)
CN (1) CN1330637A (https=)
AR (1) AR023727A1 (https=)
AT (1) ATE273954T1 (https=)
AU (1) AU760169B2 (https=)
BR (1) BR9916282A (https=)
CA (1) CA2355630A1 (https=)
CO (1) CO5170533A1 (https=)
CZ (1) CZ20012209A3 (https=)
DE (1) DE69919580T2 (https=)
ES (1) ES2226488T3 (https=)
GB (1) GB9828074D0 (https=)
GT (1) GT199900217A (https=)
HK (1) HK1038744A1 (https=)
HU (1) HUP0104867A3 (https=)
IL (1) IL142908A0 (https=)
NO (1) NO20012995L (https=)
NZ (1) NZ511478A (https=)
PE (1) PE20001387A1 (https=)
PL (1) PL348059A1 (https=)
TR (1) TR200101709T2 (https=)
WO (1) WO2000037444A1 (https=)
ZA (1) ZA200103948B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU41202A (sh) 1999-12-28 2005-03-15 Pfizer Products Inc. Ne-peptidni inhibitori vezivanja za ćeliju zavisnog od vla-4 korisni pri tretiranju inflamatornih, autoimunih i respiratornih bolesti
GB0014869D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014881D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0014883D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014947D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014851D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014849D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0127423D0 (en) * 2001-11-15 2002-01-09 Glaxo Group Ltd Process
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
CA2525934A1 (en) 2003-05-20 2004-12-02 Genentech, Inc. Thiocarbamate inhibitors of alpha-4 integrins
AU2005249566B2 (en) 2004-06-04 2010-11-11 Genentech, Inc. Method for treating multiple sclerosis
US8482496B2 (en) 2006-01-06 2013-07-09 Pixtronix, Inc. Circuits for controlling MEMS display apparatus on a transparent substrate
US20070205969A1 (en) 2005-02-23 2007-09-06 Pixtronix, Incorporated Direct-view MEMS display devices and methods for generating images thereon
US9158106B2 (en) 2005-02-23 2015-10-13 Pixtronix, Inc. Display methods and apparatus
US8310442B2 (en) 2005-02-23 2012-11-13 Pixtronix, Inc. Circuits for controlling display apparatus
US9082353B2 (en) 2010-01-05 2015-07-14 Pixtronix, Inc. Circuits for controlling display apparatus
US8519945B2 (en) 2006-01-06 2013-08-27 Pixtronix, Inc. Circuits for controlling display apparatus
US9261694B2 (en) 2005-02-23 2016-02-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
US7742016B2 (en) 2005-02-23 2010-06-22 Pixtronix, Incorporated Display methods and apparatus
US7999994B2 (en) 2005-02-23 2011-08-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
US9229222B2 (en) 2005-02-23 2016-01-05 Pixtronix, Inc. Alignment methods in fluid-filled MEMS displays
US8159428B2 (en) 2005-02-23 2012-04-17 Pixtronix, Inc. Display methods and apparatus
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US8526096B2 (en) 2006-02-23 2013-09-03 Pixtronix, Inc. Mechanical light modulators with stressed beams
US9176318B2 (en) * 2007-05-18 2015-11-03 Pixtronix, Inc. Methods for manufacturing fluid-filled MEMS displays
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
US8169679B2 (en) 2008-10-27 2012-05-01 Pixtronix, Inc. MEMS anchors
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
BR112012019383A2 (pt) 2010-02-02 2017-09-12 Pixtronix Inc Circuitos para controlar aparelho de exibição
WO2011097252A2 (en) 2010-02-02 2011-08-11 Pixtronix, Inc. Methods for manufacturing cold seal fluid-filled display apparatus
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
KR20140119777A (ko) 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
US9134552B2 (en) 2013-03-13 2015-09-15 Pixtronix, Inc. Display apparatus with narrow gap electrostatic actuators
BR112016028081A2 (pt) * 2014-05-30 2017-08-22 Sphaera Pharma Private Ltd Novos compostos como agentes antituberculares
JP6752276B2 (ja) 2015-07-08 2020-09-09 アクセロビジョン インコーポレイテッド 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物
IL293708B2 (en) 2015-10-06 2026-04-01 Genentech Inc A method for treating multiple sclerosis
US11021514B2 (en) * 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
CN109722455B (zh) * 2017-10-31 2022-03-11 中国科学院天津工业生物技术研究所 微生物发酵生产谷内酯的方法、工程菌及应用
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
EP3873605B1 (en) 2018-10-30 2024-10-23 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
FI3873884T3 (fi) 2018-10-30 2025-02-24 Gilead Sciences Inc 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
IL302175A (en) * 2020-10-21 2023-06-01 Azura Ophthalmics Ltd Compounds and methods for the treatment of ocular disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593858A1 (de) * 1967-03-02 1970-10-29 Hoechst Ag Verfahren zur Herstellung tyrosinhaltiger Peptide und deren Derivaten
US4105602A (en) * 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
WO1998053818A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
JP2001517245A (ja) * 1997-05-29 2001-10-02 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としてのビアリールアルカン酸類
AU7667498A (en) * 1997-05-30 1998-12-30 Celltech Therapeutics Limited Anti-inflammatory tyrosine derivatives

Also Published As

Publication number Publication date
KR20010101258A (ko) 2001-11-14
BR9916282A (pt) 2001-10-02
EP1140837A1 (en) 2001-10-10
WO2000037444A1 (en) 2000-06-29
HUP0104867A3 (en) 2002-06-28
CN1330637A (zh) 2002-01-09
ZA200103948B (en) 2002-11-15
IL142908A0 (en) 2002-04-21
HUP0104867A2 (hu) 2002-04-29
JP2002533326A (ja) 2002-10-08
EP1140837B1 (en) 2004-08-18
TR200101709T2 (tr) 2001-12-21
CZ20012209A3 (cs) 2001-09-12
NO20012995L (no) 2001-08-15
DE69919580T2 (de) 2005-09-01
CA2355630A1 (en) 2000-06-29
NZ511478A (en) 2003-08-29
PL348059A1 (en) 2002-05-06
US6867192B1 (en) 2005-03-15
JP4431282B2 (ja) 2010-03-10
DE69919580D1 (de) 2004-09-23
HK1038744A1 (zh) 2002-03-28
AU3039100A (en) 2000-07-12
CO5170533A1 (es) 2002-06-27
GB9828074D0 (en) 1999-02-17
ATE273954T1 (de) 2004-09-15
NO20012995D0 (no) 2001-06-15
ES2226488T3 (es) 2005-03-16
PE20001387A1 (es) 2000-12-22
GT199900217A (es) 2001-06-09
AU760169B2 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
AR028948A1 (es) Compuestos novedosos
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
ES2157027T3 (es) Oxazolidinonas sustituidas y su uso como farmacos antibacterianos.
SV1999000009A (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol ref. pg3388/sv
AR011116A1 (es) Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
TR200100411T2 (tr) 2-(Pürin-9-il)-tetrahidrofuran-3,4-diol türevleri.
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
TR200100410T2 (tr) 2-(purin-9-il)-tetrahidrofuran-3,4-diol türevleri.
ATE253586T1 (de) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivat
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
ES2183331T3 (es) Inhibidores de sulfamida-metaloproteasa.
MX9701497A (es) Polimeros de ioneno que contienen aniones biologicamente activos.
PA8432901A1 (es) Compuestos de piridilpirrol
UY28150A1 (es) Agentes terapeuticos
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
IT1285770B1 (it) Composti corticoidei
UY28694A1 (es) Nuevos compuestos
MXPA04002042A (es) Compuestos de bencimidazol sustituidos y su uso para el tratamiento del cancer.
ES2177656T3 (es) Derivados de antraciclinona y su utilizacion en el tratamiento de la amiloidosis.
MX9606300A (es) Arilalquiltioalquiltiopiridinas substituidas para combatir bacterias helicobactas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal